Pipeline & Technology

Our Pipeline

Cara Therapeutics Drug Development

Drug Indication Preclinical Phase I Phase II Phase III Commercialization
Pruritus
Pruritus KORSUVA™ Injection
(Difelikefalin/CR845)
Pruritus CKD-HD
Oral KORSUVA™ (Difelikefalin/CR845) Pruritus CKD-HD
Oral KORSUVA™
(Difelikefalin/CR845)
Pruritus CKD Stages III - V
Oral KORSUVA™
(Difelikefalin/CR845)
Pruritus CLD
Pain
Pain IV Difelikefalin/
CR845
Post-Op Pain
Oral Difelikefalin/
CR845
Chronic Pain
Oral CR701 Chronic Pain
  1. CKD = Chronic Kidney Disease
  2. CKD- HD = Chronic Kidney Disease – Hemodialysis
  3. CLD = Chronic Liver Disease

The United Stated Food and Drug Administration (FDA) has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.